Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PD-L1-H
i
Other names:
PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
29126
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
PD-L1-H
HER2 Positive Breast Cancer
PD-L1-H
HER2 Positive Breast Cancer
trastuzumab
Resistant: B - Late Trials
trastuzumab
Resistant
:
B
trastuzumab
Resistant: B - Late Trials
trastuzumab
Resistant
:
B
PD-L1-H
Non Small Cell Lung Cancer
PD-L1-H
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
pembrolizumab
Sensitive
:
C2
pembrolizumab
Sensitive: C2 – Inclusion Criteria
pembrolizumab
Sensitive
:
C2
PD-L1-H
Non-Hodgkin’s Lymphoma
PD-L1-H
Non-Hodgkin’s Lymphoma
L/P-VIPD
Resistant: C3 – Early Trials
L / P-VIPD
Resistant
:
C3
L/P-VIPD
Resistant: C3 – Early Trials
L / P-VIPD
Resistant
:
C3
PD-L1-H
Urothelial Cancer
PD-L1-H
Urothelial Cancer
atezolizumab
Sensitive: C3 – Early Trials
atezolizumab
Sensitive
:
C3
atezolizumab
Sensitive: C3 – Early Trials
atezolizumab
Sensitive
:
C3
PD-L1-H
Non Small Cell Lung Cancer
PD-L1-H
Non Small Cell Lung Cancer
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
PD-L1-H
Bladder Cancer
PD-L1-H
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
PD-L1-H
Neuroendocrine Tumor
PD-L1-H
Neuroendocrine Tumor
everolimus
Resistant: C3 – Early Trials
everolimus
Resistant
:
C3
everolimus
Resistant: C3 – Early Trials
everolimus
Resistant
:
C3
PD-L1-H
Colorectal Cancer
PD-L1-H
Colorectal Cancer
durvalumab + tremelimumab
Resistant: C3 – Early Trials
durvalumab + tremelimumab
Resistant
:
C3
durvalumab + tremelimumab
Resistant: C3 – Early Trials
durvalumab + tremelimumab
Resistant
:
C3
PD-L1-H
Solid Tumor
PD-L1-H
Solid Tumor
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
PD-L1-H
Urothelial Cancer
PD-L1-H
Urothelial Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
PD-L1-H
Small Cell Lung Cancer
PD-L1-H
Small Cell Lung Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
PD-L1-H
Melanoma
PD-L1-H
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
PD-L1-H
Lung Cancer
PD-L1-H
Lung Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login